Display options
Cite
Friedel HA, Campoli-Richards DM, Goa KL. Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1989;37(4):491-522doi: 10.2165/00003495-198937040-00005.
Friedel, H. A., Campoli-Richards, D. M., & Goa, K. L. (1989). Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs, 37(4), 491-522. https://doi.org/10.2165/00003495-198937040-00005
Friedel, H A, et al. "Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs vol. 37,4 (1989): 491-522. doi: https://doi.org/10.2165/00003495-198937040-00005
Friedel HA, Campoli-Richards DM, Goa KL. Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1989 Apr;37(4):491-522. doi: 10.2165/00003495-198937040-00005. PMID: 2661196.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Drugs. 1989 Apr;37(4):491-522. doi: 10.2165/00003495-198937040-00005.

Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Drugs

H A Friedel, D M Campoli-Richards, K L Goa

Affiliations

  1. ADIS Drug Information Services, Auckland, New Zealand.

PMID: 2661196 DOI: 10.2165/00003495-198937040-00005

Abstract

Sultamicillin is the tosylate salt of the double ester of sulbactam plus ampicillin. Sulbactam is a semisynthetic beta-lactamase inhibitor which, in combination with ampicillin, extends the antibacterial activity of the latter to include some beta-lactamase-producing strains of bacteria that would otherwise be resistant. The combination of sulbactam plus ampicillin for parenteral use has previously been shown to be clinically and bacteriologically effective in a variety of infections. The chemical linkage of sulbactam and ampicillin has now produced an orally effective compound, sultamicillin, with antibacterial activity and clinical efficacy which are similar to those of the parenteral formulation. Sultamicillin has been shown to be clinically effective in non-comparative trials in patients with infections of the respiratory tract, ears, nose and throat, urinary tract, skin and soft tissues, as well as in obstetric and gynaecological infections, and in the treatment of gonorrhoea. In a small number of controlled trials, sultamicillin has shown comparable clinical efficacy to phenoxymethyl penicillin (penicillin V) and to amoxycillin (alone and in combination with clavulanic acid) in the treatment of paediatric streptococcal pharyngitis and acute otitis media, respectively; to cefaclor in the treatment of acute otitis media in adults; and to bacampicillin, cloxacillin and flucloxacillin plus ampicillin in skin and soft tissue infections in adults, children and adult diabetic patients, respectively. Sultamicillin was superior in efficacy to bacampicillin in the treatment of chronic respiratory infections, to cefaclor in the treatment of acute otitis media in adults, and to cefadroxil in the treatment of patients with complicated urinary tract infections. However, in single-dose treatment of uncomplicated gonorrhoea, sultamicillin (1500mg plus probenecid 1g) was inferior to a 2g intramuscular dose of spectinomycin. While in several studies the incidence of diarrhoea associated with sultamicillin was greater than that with comparative antibacterials, sultamicillin-associated diarrhoea was generally mild and transitory, although occasionally severe enough to necessitate discontinuation of treatment. Further studies in larger groups of patients are needed to clarify the therapeutic efficacy and safety of sultamicillin in comparison with other antibacterial regimens, and to determine the optimum single dosage for the treatment of gonorrhoea. Nonetheless, sultamicillin appears to provide a similar pharmacodynamic and pharmacokinetic profile to that of parenteral sulbactam plus ampicillin and, as such, will extend the therapeutic efficacy of ampicillin, with the further advantage of allowing treatment of patients with an oral formulation, thus avoiding the potentially adverse clinical and financial effects of prolonged parenteral therapy.

Similar articles

Show all 10 similar articles

Cited by

References

  1. Kansenshogaku Zasshi. 1985 Jul;59(7):708-48 - PubMed
  2. J Antibiot (Tokyo). 1980 Oct;33(10):1183-92 - PubMed
  3. Infection. 1984 Jan-Feb;12(1):46-50 - PubMed
  4. J Antimicrob Chemother. 1986 Apr;17(4):543-4 - PubMed
  5. J Antimicrob Chemother. 1988 Jan;21(1):135-8 - PubMed
  6. J Clin Microbiol. 1988 Apr;26(4):750-4 - PubMed
  7. Antimicrob Agents Chemother. 1987 Apr;31(4):663-4 - PubMed
  8. Genitourin Med. 1985 Feb;61(1):44-7 - PubMed
  9. Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S503-11 - PubMed
  10. J Antimicrob Chemother. 1985 Nov;16(5):643-7 - PubMed
  11. Eur J Clin Microbiol. 1983 Aug;2(4):340-4 - PubMed
  12. Antimicrob Agents Chemother. 1986 Jun;29(6):1110-2 - PubMed
  13. APMIS Suppl. 1989;5:17-22 - PubMed
  14. APMIS Suppl. 1989;5:23-34 - PubMed
  15. Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S639-43 - PubMed
  16. Antimicrob Agents Chemother. 1980 Apr;17(4):615-22 - PubMed
  17. J Antimicrob Chemother. 1982 Jul;10(1):49-55 - PubMed
  18. J Antimicrob Chemother. 1982 Feb;9 Suppl B:31-40 - PubMed
  19. Br J Vener Dis. 1983 Oct;59(5):293-7 - PubMed
  20. Pediatr Infect Dis. 1986 Jan-Feb;5(1):33-8 - PubMed
  21. Kansenshogaku Zasshi. 1985 Jul;59(7):749-65 - PubMed
  22. N Engl J Med. 1972 Mar 9;286(10):505-7 - PubMed
  23. Tohoku J Exp Med. 1985 Sep;147(1):1-13 - PubMed
  24. Antimicrob Agents Chemother. 1984 May;25(5):599-602 - PubMed
  25. Pharmacol Rev. 1984 Jun;36(2 Suppl):177S-182S - PubMed
  26. J Antimicrob Chemother. 1986 Apr;17(4):529-33 - PubMed
  27. J Antimicrob Chemother. 1983 May;11(5):435-45 - PubMed
  28. Lancet. 1980 May 10;1(8176):1037 - PubMed
  29. J Antimicrob Chemother. 1984 Oct;14(4):395-401 - PubMed
  30. Antimicrob Agents Chemother. 1986 Nov;30(5):789-91 - PubMed
  31. Ann Intern Med. 1986 Dec;105(6):924-31 - PubMed
  32. J Infect Dis. 1981 Sep;144(3):237-43 - PubMed
  33. APMIS Suppl. 1989;5:45-50 - PubMed
  34. Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S559-71 - PubMed
  35. Drugs. 1988;35 Suppl 7:29-33 - PubMed
  36. J Antimicrob Chemother. 1984 Feb;13(2):161-70 - PubMed
  37. J Antimicrob Chemother. 1980 Mar;6(2):197-206 - PubMed
  38. APMIS Suppl. 1989;5:63-7 - PubMed
  39. Drugs. 1987 Jun;33(6):577-609 - PubMed
  40. APMIS Suppl. 1989;5:57-62 - PubMed
  41. J Antimicrob Chemother. 1984 Sep;14(3):261-5 - PubMed
  42. Am J Med. 1985 Feb 8;78(2A):65-76 - PubMed
  43. Hinyokika Kiyo. 1986 Jan;32(1):151-61 - PubMed
  44. J Clin Microbiol. 1987 Oct;25(10):1920-5 - PubMed
  45. Antimicrob Agents Chemother. 1985 Dec;28(6):832-3 - PubMed
  46. J Antimicrob Chemother. 1985 Mar;15(3):345-51 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources